Key result
Therapies targeting TGF-β represent a potential approach to treat cardiac alterations and fibrosis in patients affected by Chagas disease.
Why the study?
Transforming growth factor beta is deeply involved in the pathogenesis of Chagas disease, prompting exploration of its potential as a therapeutic target for cardiac alterations.
This perspective highlights the potential of targeting the TGF-β pathway to treat cardiac damage and fibrosis in patients with Chagas disease.
Supports TGF-β targeting for Chagas cardiomyopathy trials; should not yet change practice.
Transforming growth factor beta (TGF-β) is deeply involved on the pathogenesis of Chagas disease. Our group has been investigating the participation of this pleiotropic cytokine in different aspects of Chagas disease over the last 20 years. Important observations have been made, such as: (i) the ability of Trypanosoma cruzi in activating latent TGF-β; (ii) the potential involvement of TGF-β pathway on T. cruzi invasion of host cells; (iii) association of TGF-β with parasite intracellular replication; (iv) cardiac fibrosis development and maintenance; (v) disruption of Connexin-43 plaque structures and (vi) inflammation and immune response. In this perspective article we intend to discuss the advances of the potential use of new therapies targeting TGF-β to treat the cardiac alterations of Chagas disease-affected patients.
No takes yet. Share an insight, caveat, or question.
Waghabi et al. (2022) conducted a review in Chagas disease. Therapies targeting TGF-β was evaluated. Therapies targeting TGF-β represent a potential approach to treat cardiac alterations and fibrosis in patients affected by Chagas disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: